Codexis to Report Second Quarter 2025 Financial Results on August 13
Rhea-AI Summary
Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutic manufacturing, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, after market close.
The company will host a conference call and webcast at 4:30 PM ET to discuss results and provide business updates. Investors can access the webcast through Codexis' Investor Relations website, where it will remain available for 90 days. For the live call, participants can dial 877-705-2976 (domestic) or 201-689-8798 (international).
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CDXS declined 3.94%, reflecting a moderate negative market reaction. Argus tracked a trough of -4.4% from its starting point during tracking. This price movement removed approximately $9M from the company's valuation, bringing the market cap to $231M at that time.
Data tracked by StockTitan Argus on the day of publication.
REDWOOD CITY, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for the efficient and scalable manufacturing of complex therapeutics, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 13, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
FAQ
When will Codexis (CDXS) report Q2 2025 earnings?
What time is the Codexis Q2 2025 earnings call?
How can I access Codexis' Q2 2025 earnings call?
How long will Codexis' Q2 2025 earnings webcast be available?
